Abstract

Background: Post-Treatment Lyme Disease Syndrome (PTLDS) presents a significant clinical challenge, characterized by persistent multisystem symptoms despite standard antimicrobial and integrative therapies. While a prior pilot study demonstrated significant clinical benefit from a 10-session protocol of Variable Frequency Electromagnetic (VFEM) therapy, the magnitude of the response suggested an extended protocol was warranted. This report evaluates clinical outcomes associated with a 20-session VFEM protocol in patients with refractory PTLDS.

Methods: This prospective case series included 24 patients with clinically confirmed, refractory PTLDS and frequent tick-borne co-infections. Patients underwent 20 outpatient VFEM sessions (30 minutes each) utilizing focused high-intensity inductive therapy platforms operating at 5–100 Hz with magnetic field intensities of 1.8 Tesla (device parameters patent pending). Symptom burden was measured at every session using the validated General Symptom Questionnaire-30 (GSQ-30), with functional recovery status and Jarisch-Herxheimer-type (JHR-type) reaction incidence as secondary outcomes. All evaluable patients provided follow-up data at up to 12 months post-treatment.

Results: Mean GSQ-30 scores declined significantly from 58.2 (SD 15.1) at baseline to 17.5 (SD 12.0) following the 20-session protocol (mean reduction 40.7 points; 95% CI 35.1–46.3; p < 0.001; Cohen's dz = 3.08), representing a mean percent improvement of 70.9%. Twenty-two of 24 patients (91.7%) achieved complete symptom resolution or major functional recovery; two patients achieved moderate but clinically meaningful improvement. All patients (100%) experienced transient JHR-type reactions during the early treatment phase, which diminished progressively in intensity. All 24 evaluable patients maintained improvements at 6-month follow-up assessment; extended follow-up at approximately 12 months indicated sustained functional improvement in the majority of patients, with a subset reporting partial symptom recurrence — all of whom stabilized above their pre-treatment baseline and maintained functional capacity. A subset of 7 patients with follow-up data ranging from 15 to 24 months demonstrated continued remission, with no return to pre-treatment symptom burden.

Conclusions: Extended VFEM therapy was associated with substantial, statistically significant, and durable reductions in symptom burden among patients with refractory PTLDS. The characteristic early pattern of Herxheimer-type reactions followed by progressive clinical improvement provides compelling clinical evidence that VFEM exerts direct antimicrobial activity, most plausibly through direct bacterial disruption as well as disruption of biofilm-protected persistent Borrelia. These findings support the initiation of randomized, sham-controlled trials to rigorously evaluate the efficacy and mechanism of action of VFEM as a novel standalone antimicrobial modality.